MMED

8-K - MiniMed Group, Inc. (0002062583) (Filer)

Agreement builds on the companies' ongoing partnership to expand choice and simplify diabetes management NORTHRIDGE, Calif., June 3, 2026 /CNW/ -- MiniMed (NASDAQ:MMED), a global leader in diabetes technology, today announced an expanded agreement with Abbott to collaborate on commercializing dual glucose-ketone sensors designed to integrate exclusively with MiniMed smart dosing systems. These new dual monitoring sensors are designed to enable early, real-time detection of rising ketones to help prevent diabetic ketoacidosis (DKA), a life-threatening complication.1 The agreement builds on the companies' existing partnership for

Continued momentum in Q4, with net sales of $837 million growing 16% as reported and 9% organic year-over-yearRecord annual net sales performance surpasses $3B for first time, growing 14% as reported and 8% organicAdvanced global pipeline ahead of schedule with FDA clearance for MiniMed Flex™, CE Mark for Instinct, and global launch of MiniMed Go™ Smart MDINORTHRIDGE, Calif., June 3, 2026 /PRNewswire/ -- MiniMed (NASDAQ:MMED), a global leader in diabetes technology, today reported financial results for its fourth quarter and full fiscal year ended April 24, 2026. "MiniMed delivered a strong finish to our fiscal year, driven by strength in international markets

Following this week's launch of MiniMed Go™, MiniMed will bring hands-on demonstrations of the system and new clinical dataNORTHRIDGE, Calif., May 27, 2026 /PRNewswire/ -- MiniMed (NASDAQ:MMED), a global leader in diabetes technology, today announced an overview of its upcoming presence at the American Diabetes Association's (ADA) Scientific Sessions in New Orleans June 5-8. The meeting marks MiniMed's first U.S. diabetes congress since becoming a standalone public company — and the first to feature its newest generation of technology designed to give people with diabetes more freedom every day. At ADA, MiniMed will showcase te

NORTHRIDGE, Calif., May 26, 2026 /PRNewswire/ -- MiniMed (NASDAQ:MMED), a global leader in diabetes technology, today announced that management will participate in a fireside chat at the upcoming Goldman Sachs 47th Annual Global Healthcare Conference. The fireside chat will take place on Monday, June 8, 2026, at 11:20 a.m. EDT.A live webcast and replay will be accessible on the MiniMed Investor Relations website: investors.minimed.com/events.About MiniMedMiniMed is a global leader in insulin delivery, constantly advancing therapies that support people with diabetes in more than

Randomized crossover trial reinforces SmartGuard™ algorithm as key driver of automated insulin delivery performanceNORTHRIDGE, Calif., May 21, 2026 /PRNewswire/ -- MiniMed (NASDAQ:MMED), a global leader in diabetes technology, today announced results from a new randomized crossover study demonstrating that glycemic outcomes for study participants were virtually identical when using the MiniMed™ 780G system with either the Simplera Sync™ sensor or Instinct sensor, made by Abbott. This data, published today in Diabetes Technology & Therapeutics, reinforces that the automated insulin delivery (AID) algorithm, not the sensor, is the primary determinant of clinical outcomes.1

8-K - MiniMed Group, Inc. (0002062583) (Filer)

The Benchmark Company initiated coverage of MiniMed with a rating of Buy and set a new price target of $20.00

SCHEDULE 13G - MiniMed Group, Inc. (0002062583) (Subject)

BRAMPTON, Ontario, April 28, 2026 (GLOBE NEWSWIRE) -- MiniMed Group, Inc. ((MiniMed, NASDAQ:MMED), a global leader in insulin delivery, announced Health Canada has licensed new software for the MiniMed™ 780G system, marking a meaningful step forward in diabetes care for Canadians. With this authorization, the MiniMed™ 780G system now offers greater flexibility, combining Meal Detection™ technology, and SmartGuard™, with both the Guardian™ 4 and Simplera Sync™ sensors. Additionally, the system is now compatible with Fiasp® and indicated for adults 18 years and older with Type 2 diabetes. Simplera Sync™ is a disposable, all-in-one sensor that requires no fingersticks* with SmartGuard, no ov

8-K - MiniMed Group, Inc. (0002062583) (Filer)

10-Q - MiniMed Group, Inc. (0002062583) (Filer)

NORTHRIDGE, Calif., April 13, 2026 /PRNewswire/ -- MiniMed (NASDAQ:MMED), a global leader in diabetes technology, today announced that it will report financial results for its fourth quarter and full fiscal year 2026 on Wednesday, June 3, 2026. A news release will be issued at approximately 3:45 a.m. Pacific Daylight Time (PDT) and will be available at https://news.minimed.com. The news release will include summary financial information for the company's fourth quarter and full fiscal year 2026, which will end on Friday, April 24, 2026. MiniMed will host a webcast at 5:45 a.m. P

BTIG Research initiated coverage of MiniMed with a rating of Buy and set a new price target of $25.00

Deutsche Bank initiated coverage of MiniMed with a rating of Buy and set a new price target of $20.00

BofA Securities initiated coverage of MiniMed with a rating of Buy and set a new price target of $27.00

Piper Sandler initiated coverage of MiniMed with a rating of Neutral and set a new price target of $16.00

Mizuho initiated coverage of MiniMed with a rating of Outperform and set a new price target of $21.00

Morgan Stanley initiated coverage of MiniMed with a rating of Overweight and set a new price target of $19.00

Citigroup initiated coverage of MiniMed with a rating of Buy and set a new price target of $23.00

Evercore ISI initiated coverage of MiniMed with a rating of Outperform and set a new price target of $20.00

Wells Fargo initiated coverage of MiniMed with a rating of Overweight and set a new price target of $26.00

William Blair initiated coverage of MiniMed with a rating of Outperform

Goldman initiated coverage of MiniMed with a rating of Buy and set a new price target of $24.00

4 - MiniMed Group, Inc. (0002062583) (Issuer)